RhumbLine Advisers
FLNA

RhumbLine Advisers’s Filana Therapeutics FLNA Stock Holding History

RhumbLine Advisers’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.93K Hold
1,734
– – ﹤0.01% 3912
2025
Q4 		$3.43K Hold
1,734
– – ﹤0.01% 3946
2025
Q3 		$5.04K Hold
1,734
– – ﹤0.01% 3915
2025
Q2 		$3.14K Sell
1,734
-57,224
-97% -$102K ﹤0.01% 3956
2025
Q1 		$88.4K Buy
58,958
+1,129
+2% +$2.85K ﹤0.01% 3432
2024
Q4 		$136K Buy
57,829
+1,672
+3% +$29.4K ﹤0.01% 3373
2024
Q3 		$1.65M Sell
56,157
-3,102
-5% -$71.4K ﹤0.01% 2007
2024
Q2 		$732K Buy
59,259
+2,322
+4% +$48.9K ﹤0.01% 2420
2024
Q1 		$1.16M Buy
56,937
+835
+1% +$19.2K ﹤0.01% 2175
2023
Q4 		$1.26M Sell
56,102
-647
-1% -$13.7K ﹤0.01% 2141
2023
Q3 		$944K Sell
56,749
-252
-0.4% -$4.99K ﹤0.01% 2244
2023
Q2 		$1.4M Buy
57,001
+4,448
+8% +$107K ﹤0.01% 2115
2023
Q1 		$1.27M Buy
52,553
+781
+2% +$21.6K ﹤0.01% 2023
2022
Q4 		$1.53M Buy
51,772
+365
+0.7% +$13.1K ﹤0.01% 1926
2022
Q3 		$2.15M Buy
51,407
+4,625
+10% +$125K ﹤0.01% 1717
2022
Q2 		$1.32M Buy
46,782
+5,638
+14% +$142K ﹤0.01% 1998
2022
Q1 		$1.53M Buy
41,144
+2,230
+6% +$94.5K ﹤0.01% 1939
2021
Q4 		$1.7M Sell
38,914
-1,531
-4% -$80.3K ﹤0.01% 1968
2021
Q3 		$2.51M Buy
40,445
+643
+2% +$53.7K ﹤0.01% 1768
2021
Q2 		$3.4M Sell
39,802
-5,636
-12% -$302K ﹤0.01% 1651
2021
Q1 		$2.04M Buy
45,438
+11,448
+34% +$450K ﹤0.01% 1900
2020
Q4 		$232K Buy
33,990
+11,044
+48% +$98.6K ﹤0.01% 2773
2020
Q3 		$264K Buy
22,946
+923
+4% +$4.16K ﹤0.01% 2570
2020
Q2 		$68K Buy
+22,023
New +$99.9K ﹤0.01% 3009
2015
Q2 		– Sell
-4,689
Closed -$62K – 3081
2015
Q1 		$62K Buy
4,689
+14
+0.3% +$189 ﹤0.01% 2989
2014
Q4 		$66K Buy
4,675
+132
+3% +$2.29K ﹤0.01% 2988
2014
Q3 		$124K Hold
4,543
– – ﹤0.01% 2900
2014
Q2 		$183K Buy
+4,543
New +$168K ﹤0.01% 2864

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

RhumbLine Advisers's FLNA Position: Q1 2026 in Review

RhumbLine Advisers held its Filana Therapeutics (FLNA) position steady in Q1 2026 at 1,734 shares worth $2.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3912.

RhumbLine Advisers first reported a position in FLNA in Q2 2014 and has held it in 28 quarters since. The position peaked at $3.4M in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • RhumbLine Advisers held 1,734 shares of Filana Therapeutics worth $2.93K as of Q1 2026.
  • RhumbLine Advisers left its Filana Therapeutics share count unchanged in Q1 2026.
  • Filana Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3912 holding.
  • RhumbLine Advisers first reported a position in Filana Therapeutics in Q2 2014 and has held it in 28 quarters since.
  • RhumbLine Advisers's Filana Therapeutics position peaked at $3.4M in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.